Daiichi Sankyo Aims to File Yescarta in Japan by Year-End

Junichi Koga, Global Head of R&D, Daiichi Sankyo Daiichi Sankyo, which has Japan rights to Gilead Sciences’ CAR-T therapy Yescarta (axicabtagene ciloleucel), is aiming to submit the treatment for regulatory approval by the end of this year, its global R&D...read more